Urinary tract infections (UTIs) pose as an important public health problem with considerable economic burden of more than 6 million US dollars.1 The global annual incidence is approximately 150 million cases; around 40% women and 12% men experienced atleast one symptomatic UTI in their life‑time.1 Patients with UTI are often treated empirically and the physician’s choice of antibiotics typically depends on national treatment recommendations. Therefore, antibiotic resistance has become a major problem in UTI mostly due to overprescription by practitioners.2 The spectrum of bacteria isolated from patients with UTI worldwide has remained largely unchanged; E.coli followed by Klebsiella pneumoniae being the most prevalent microorganisms. However, there have been significant changes in the resistance patterns of uropathogens over the past few decades.